86604-68-4 Usage
Uses
Used in Pharmaceutical Industry:
2-[(4-METHOXY-3-METHYLPYRIDINYL)-METHYLSULFINYL]-5-TRIFLUOROMETHYLBENZIMIDAZOLE is used as a proton pump inhibitor for the treatment of conditions characterized by excessive stomach acid production, such as gastroesophageal reflux disease (GERD) and peptic ulcers. Its application is based on its ability to inhibit the production of stomach acid, thereby alleviating symptoms and promoting healing of the affected areas.
Used in Gastroenterology:
In the field of gastroenterology, 2-[(4-METHOXY-3-METHYLPYRIDINYL)-METHYLSULFINYL]-5-TRIFLUOROMETHYLBENZIMIDAZOLE is used as a therapeutic agent for managing acid-related disorders. Its application is due to its effectiveness in reducing gastric acid secretion, which is crucial in the management of conditions like GERD and peptic ulcers, as well as in the preparation of the stomach for certain medical procedures.
Used in Drug Formulation:
2-[(4-METHOXY-3-METHYLPYRIDINYL)-METHYLSULFINYL]-5-TRIFLUOROMETHYLBENZIMIDAZOLE is used in the formulation of oral dosage forms such as tablets and capsules. Its application in this context is to provide a convenient and effective means of administering the medication to patients, ensuring optimal absorption and bioavailability of the active ingredient for the treatment of acid-related disorders.
Check Digit Verification of cas no
The CAS Registry Mumber 86604-68-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,6,6,0 and 4 respectively; the second part has 2 digits, 6 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 86604-68:
(7*8)+(6*6)+(5*6)+(4*0)+(3*4)+(2*6)+(1*8)=154
154 % 10 = 4
So 86604-68-4 is a valid CAS Registry Number.
InChI:InChI=1/C16H14F3N3O2S/c1-9-13(20-6-5-14(9)24-2)8-25(23)15-21-11-4-3-10(16(17,18)19)7-12(11)22-15/h3-7H,8H2,1-2H3,(H,21,22)
86604-68-4Relevant academic research and scientific papers
Activation of chloride channels for correction of defective chloride transport
-
, (2008/06/13)
This invention provides a method for increasing the permeability of epithelial cells to a chloride ion in a subject comprising administering a permeability enhancing amount of a composition comprising a specifically-defined nontoxic, benzimidazole or benzimidazole derivative. The invention also relates to a method of treating cystic fibrosis comprising administering an epithelial cell chloride permeability enhancing amount of a composition comprising a specifically-defined nontoxic, benzimidazole or benzimidazole derivative. The benzimidazole compound having chloride channel activation activity for use in this invention includes a 2-[(pyridyl)-methylsulfinyl or -methylthio]benzimidazole derivatives and salts thereof, for instance. Specifically, these include the compounds omeprazole, lansoprazole, thimoprazole and pantoprazole. When appropriately applied, these compounds can correct detective chloride transport, increasing the salt and water flux in diseased tissues to levels closer to those of normal tissues thus reducing life-threatening complications.
